Trials / Recruiting
RecruitingNCT07450820
OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD
A Multinational, Observational, Retrospective, Secondary Data Study Analyzing Dapagliflozin Effectiveness in Routine Clinical Practice Among Patients With Chronic Kidney Disease. Local Adaptation for Spain. Part 2
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 14,308 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This is a retrospective, observational study, using secondary data captured in electronic health records (EHRs). The study is a part of the OPTIMISE-CKD program to assess the current CKD treatment landscape, Dapagliflozin utilisation and characterization of incident CKD patient and the burden of disease within an observation period of 39 months (August 2020-November 2024) in two cohorts (preand post-reimbursement of Dapagliflozin for CKD)
Conditions
Timeline
- Start date
- 2026-02-18
- Primary completion
- 2027-02-09
- Completion
- 2027-02-09
- First posted
- 2026-03-05
- Last updated
- 2026-03-27
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT07450820. Inclusion in this directory is not an endorsement.